JP2010523138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523138A5 JP2010523138A5 JP2010502570A JP2010502570A JP2010523138A5 JP 2010523138 A5 JP2010523138 A5 JP 2010523138A5 JP 2010502570 A JP2010502570 A JP 2010502570A JP 2010502570 A JP2010502570 A JP 2010502570A JP 2010523138 A5 JP2010523138 A5 JP 2010523138A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- immunogenic composition
- viral vector
- vector
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013603 viral vector Substances 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 23
- 239000013598 vector Substances 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 230000002163 immunogen Effects 0.000 claims 19
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 claims 13
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical group 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 201000004792 malaria Diseases 0.000 claims 7
- 229960005486 vaccine Drugs 0.000 claims 7
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 4
- 230000001717 pathogenic effect Effects 0.000 claims 4
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 241000710929 Alphavirus Species 0.000 claims 3
- 208000000666 Fowlpox Diseases 0.000 claims 3
- 208000009889 Herpes Simplex Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 241001529453 unidentified herpesvirus Species 0.000 claims 3
- 230000037452 priming Effects 0.000 claims 2
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 101150078331 ama-1 gene Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0706912.3A GB0706912D0 (en) | 2007-04-10 | 2007-04-10 | Novel viral vaccines |
| PCT/GB2008/001271 WO2008122817A2 (en) | 2007-04-10 | 2008-04-10 | Immunogenic compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523138A JP2010523138A (ja) | 2010-07-15 |
| JP2010523138A5 true JP2010523138A5 (enExample) | 2011-05-19 |
Family
ID=38091118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010502570A Pending JP2010523138A (ja) | 2007-04-10 | 2008-04-10 | 免疫原性組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110064768A1 (enExample) |
| EP (1) | EP2155242A2 (enExample) |
| JP (1) | JP2010523138A (enExample) |
| CN (1) | CN101959420A (enExample) |
| AU (1) | AU2008235315A1 (enExample) |
| CA (1) | CA2683117A1 (enExample) |
| GB (1) | GB0706912D0 (enExample) |
| WO (1) | WO2008122817A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0719509D0 (en) * | 2007-10-05 | 2007-11-14 | Isis Innovation | Molecular adjuvant |
| WO2010127420A1 (pt) * | 2009-05-05 | 2010-11-11 | Universidade Federal De Minas Gerais - Ufmg | Sequências geneticamente modificadas de antígenos de plasmodium vivax |
| GB0918154D0 (en) | 2009-10-16 | 2009-12-02 | Isis Innovation | Mycobacterial vaccines |
| EP2557089A2 (en) * | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions and methods for immunomodulation |
| EP2931896B1 (en) | 2012-12-11 | 2019-01-16 | Osivax SAS | Modified coiled coil type proteins having improved properties |
| AU2014347004B2 (en) * | 2013-11-05 | 2019-08-08 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor |
| EP3188752A2 (en) * | 2014-09-03 | 2017-07-12 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2678797A (en) * | 1996-04-22 | 1997-11-12 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Heterologous boosting immunizations |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| GB9922361D0 (en) * | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| CA2467486A1 (en) * | 2001-11-30 | 2003-06-12 | Isis Innovation Limited | Vaccine |
| WO2003076598A2 (en) * | 2002-03-13 | 2003-09-18 | Merck & Co., Inc. | Method of inducing an enhanced immune response against hiv |
| WO2005014654A2 (en) * | 2003-08-12 | 2005-02-17 | Avidis Sa | Product comprising a c4bp core protein and a monomeric antigen, and its use |
| WO2005051414A1 (en) * | 2003-11-26 | 2005-06-09 | Avidis Sa | Use of c4bp core region as a cd40 agonist |
| EP1795540A1 (en) * | 2005-11-30 | 2007-06-13 | Imaxio | Multimeric complexes of antigens and an adjuvant |
-
2007
- 2007-04-10 GB GBGB0706912.3A patent/GB0706912D0/en not_active Ceased
-
2008
- 2008-04-10 WO PCT/GB2008/001271 patent/WO2008122817A2/en not_active Ceased
- 2008-04-10 US US12/595,351 patent/US20110064768A1/en not_active Abandoned
- 2008-04-10 JP JP2010502570A patent/JP2010523138A/ja active Pending
- 2008-04-10 AU AU2008235315A patent/AU2008235315A1/en not_active Abandoned
- 2008-04-10 CN CN2008800164220A patent/CN101959420A/zh active Pending
- 2008-04-10 CA CA002683117A patent/CA2683117A1/en not_active Abandoned
- 2008-04-10 EP EP08736939A patent/EP2155242A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6818797B2 (ja) | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 | |
| Moore et al. | Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria | |
| EP1616954B1 (en) | Methods and reagents for vaccination which generate a CD8+ Tcell immune response against hepatitis B or C | |
| JP2010523138A5 (enExample) | ||
| Mastrangelo et al. | Poxvirus vectors: orphaned and underappreciated | |
| US9017696B2 (en) | Adenovirus vectors | |
| JP2016510989A5 (enExample) | ||
| JP2011041578A5 (enExample) | ||
| JP2024105526A5 (enExample) | ||
| JP2016074727A5 (enExample) | ||
| JP2024105526A (ja) | 免疫応答を誘導するための組成物 | |
| JP2003509470A (ja) | 抗原に対するｃｄ８＋ｔ細胞免疫応答を増強するための複製欠損性アデノウイルスベクターの使用 | |
| JP2021528367A5 (enExample) | ||
| CA2527640A1 (en) | Tumor antigens for prevention and/or treatment of cancer | |
| WO2008086386A8 (en) | Adenoviral vector-based malaria vaccines | |
| JP2019528271A5 (enExample) | ||
| US20100322896A1 (en) | Molecular adjuvant | |
| Shaukat et al. | COVID-19 vaccines: Development, strategies, types and vaccine usage hesitancy | |
| HUE030037T2 (en) | Use of modified anemic virus for rapid induction of immunity against gluten virus or other agents | |
| EP2042604A1 (en) | VV promoter driven overexpression of recombinant antigens | |
| AU2017228587B2 (en) | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines | |
| Drillien et al. | Les poxvirus: une famille de vecteurs | |
| AU775973B2 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response | |
| Moorthy | Analysis of DNA and recombinant viral vaccines against Plasmodium falciparum in malaria-naive and malaria-exposed humans |